NantHealth & NantOmics launch AI platform for subtyping Lung Cancer
Category: #health  By Mateen Dalal  Date: 2020-01-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

NantHealth & NantOmics launch AI platform for subtyping Lung Cancer

NantHealth, Inc., a personalized, evidence-based, next-generation healthcare company and NantOmics, LLC, one of the leading companies in molecular analysis, have reportedly launched an innovative AI platform for assisting pathologists in image-based lung cancer subtyping. The platform was demonstrated at the Society for IS&T’s (Imaging Science and Technology) International Symposium on Electrical Imaging 2020.

Reportedly, this AI-based platform precisely subtypes lung cancer pathology and accomplishes high concordance with analysis conducted by trained medical pathologists.

An initial study of the AI technology was presented at the sixth AACR (American Association for Cancer Research) and the IASLC (International Association for the Study of Lung Cancer) International Joint Conference. The study stated that even with lower overall tumor mutation burden (TMB) and lymphocyte levels, there is a subset of lung cancers with extremely high infiltrating lymphocyte counts.

The findings showed that an innovative Artificial Intelligence-based technique for subtyping lung cancer pathologies impacts treatment options for patients and enhanced methods of finding tumor-infiltrating white cells observed elevated in lung cancer.

Dr. Patrick Soon-Shiong, MD, CEO and Chairman of NantHealth, said that precisely quantifying and identifying tumor-infiltrating white cells is important for prognosis and treatment decisions. Still, it currently involves manual assessment of whole slide images by professional pathologists and incurs significant cost and delays.

Soon-Shiong cites that the company’s aim was to create a novel cloud-based diagnostic imaging system. To achieve this, the machine vision of digitally transferred images of tumor tissue would enable a scalable cloud-based infrastructure, with an automated, image patch-based system to categorize cancers by their immune status.

Soon-Shiong explained that with extremely accurate lymphocyte and tumor-region detection, oncologists could better treat their patients with the help of adeno versus squamous-based treatments and the use of immunotherapies could result in better outcomes.

For a record, NantOmics delivers molecular diagnostic capabilities with an aim to provide molecularly driven decision support and actionable intelligence for treating cancer. Meanwhile, NantHealth provides solutions across the continuum of care for patients, physicians, payors, patients, and biopharmaceutical organizations.
 

Source Credit: https://apnews.com/Business%20Wire/4971d90aa0794eb384e2a8c37b323622

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
Mercedes-AMG Petronas F1 Team and AMD team-up for F1 2020
By Mateen Dalal

Mercedes-AMG Petronas F1 Team, and Advanced Micro Devices (AMD), a renowned semiconductor developer, have reportedly announced a new multi-year partnership agreement that has combined the two firms’ passion of for high performance, beginning fr...

Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
Aduro begins trial of MK-5890 for non-small cell lung cancer treatment
By Mateen Dalal

The biopharmaceutical giant has also received a USD 10 million development milestone payment from Merck & CO. for the initiation of the trial A clinical-stage biopharmaceutical company, Aduro Biotech, Inc. recently announced to have ba...

TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
TherapeuticsMD submits a New Drug Application to the FDA for BIJUVA®
By Mateen Dalal

TherapeuticsMD, Inc., an inventive pharmaceutical company that focuses on women healthcare, has recently announced that it has presented a New Drug Application (NDA) pre-approval efficacy supplement to the U.S. FDA (Food and Drug Administration) for ...